Status: Recruiting
CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALL
This is a phase II clinical study to evaluate the safety and efficacy of CAR-T-19 injection in the treatment of CD19-positive relapsed/refractory B-cell acute lymphoblastic leukemia.
Participants needed: 100
Trial details
Phase: Phase 2Age: Up to 25Biological sex: AllType: InterventionalSponsor: Beijing Yongtai Ruike Biotechnology Company LtdUpdated: Jan 13, 2025Locations: 1
Eligibility criteria
Voluntary participation in clinical trial, The Participants or his legal guardia... [+11]
Isolated extra-medullary disease relapse . [+17]